Medidata to Present Breakthrough Innovation at 2019 ASCO Annual Meeting
May 24 2019 - 8:30AM
Business Wire
How data and technology enable more patients to
receive the most promising new experimental therapies during a
clinical trial - a collaboration with Friends of Cancer
Research
- Friends of Cancer Research and Medidata
present scientific innovation that reduces the number of patients
in a control group for a clinical trial
- Poster presentation scheduled for June
2 at 8:00 a.m. - 11:00 a.m. CDT during the Lung Cancer—Non-Small
Cell Metastatic session
- The Medidata booth is located at #6147
in the Exhibit Hall
For the third consecutive year, Medidata
(NASDAQ: MDSO) will present breakthrough scientific findings at the
American Society of Clinical Oncology (ASCO) Annual Meeting in
Chicago. The joint poster presentation with the Friends of Cancer
Research (Friends) will occur on June 2 at 8:00 a.m. - 11:00 a.m.
CDT during the Lung Cancer - Non-Small Cell Metastatic session.
Medidata and Friends will present the poster
9108, Non-Small Cell Lung Cancer (NSCLC) Case Study Examining
Whether Results in a Randomized Control Arm are Replicated by a
Synthetic Control Arm (SCA), which addresses:
- The methodology for building a
synthetic control arm based on high quality, cross-study,
standardized clinical trial data from previous NSCLC studies
- Research comparing the synthetic
control arm to a randomized control group from an NSCLC trial
- The potential for using synthetic
control arms to augment or replace randomized controls in future
clinical trials
- The promise of intelligent trials,
powered by machine learning and AI
Presenters:
- Ruthie Davi, vice president, Acorn AI,
a Medidata company
- Mark Stewart, vice president, science
policy, Friends of Cancer Research
"In collaboration with Friends, we have
demonstrated that using historical clinical trial data and
analytical statistical methods to create a synthetic control arm
can significantly augment our understanding about product
performance. It is our expectation that, in cases where a
concurrent randomized control is not practicable, these
methodologies will help speed innovative products to patients,”
said Sastry Chilukuri, president, Acorn AI, a Medidata company.
Medidata will also demonstrate at booth #6147
in the Exhibit Hall:
- Medidata Rave Clinical
CloudTM: Optimize operational execution, decrease
the data entry and maintenance burden, and reduce the number of
clinical systems across study teams with a single source of truth
for all oncology study-related data.
- Acorn AI: Answer the most
important questions in oncology across R&D and
commercialization to improve outcomes for patients and accelerate
digital transformation and growth for customers. Apply machine
learning algorithms to drive timely decision on efficacy and safety
during trial conduct. Seamlessly provide artificial intelligence as
a service for a variety of clinical and commercial use cases,
saving customers from developing similar AI solutions and enabling
their data science teams to focus on higher value activities.
- SHYFT: Conduct, design, and gain
insight from outcomes-based observational research in hours rather
than months. Drive converged intelligence across Epidemiology,
HEOR, Pharmacovigilance, market research, corporate development,
and commercial teams.
About Medidata
Medidata is leading the digital transformation
of life sciences, with the world's most-used platform for clinical
development, commercial, and real-world data. Powered by artificial
intelligence and delivered by the top ranked industry experts,
Medidata helps pharmaceutical, biotech, medical device companies,
and academic researchers accelerate value, minimize risk and
optimize outcomes. Medidata and its companies, Acorn AI and SHYFT,
serve more than 1,200 customers and partners worldwide and empower
more than 150,000 certified users every day to create hope for
millions of patients. Discover the future of life sciences:
www.medidata.com
About Friends of Cancer Research
Friends of Cancer Research (Friends) drives
collaboration among partners from every healthcare sector to power
advances in science, policy, and regulation that speed lifesaving
treatments to patients. For more information, please
visit www.focr.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190524005159/en/
Investors:Betsy Frank,
917-522-4620bfrank@medidata.comorMedia:Erik Snider,
646-362-2997esnider@medidata.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024